Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.54 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.54 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.54 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.51 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927030 | 0.94 | CCKAR (0.53) | PDK1PDK2PDK3PDK4ITGB1 | |
| SCHEMBL5926733 | 0.94 | PDK1 (0.56) | PDK1PDK2PDK3PDK4ITGB1 | |
| SCHEMBL5927122 | 0.92 | PDK1 (0.53) | PDK1PDK2PDK3PDK4ITGB1 | |
| SCHEMBL5927314 | 0.92 | PYGL (0.53) | PDK1PDK2PDK3PDK4ITGB1 | |
| SCHEMBL3994928 | 0.89 | ITGB1 (0.61) | PDK1PDK2PDK3PDK4ITGB1 | |
| SCHEMBL5926463 | 0.89 | PDK1 (0.53) | PDK1PDK2PDK3PDK4ITGB1 | |
| SCHEMBL5927290 | 0.86 | PDK1 (0.51) | PDK1PDK2PDK3PDK4ITGB1 | |
| SCHEMBL4827784 | 0.85 | ECE1 (0.53) | PDK1PDK2PDK3PDK4ITGB1 | |
| SCHEMBL4827782 | 0.85 | ECE1 (0.53) | PDK1PDK2PDK3PDK4ITGB1 | |
| SCHEMBL3992014 | 0.85 | SERPINE1 (0.50) | SERPINE1KDM4ENPSR1RXFP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | PDK1 2955/4885PDK2 2541/4885PDK3 1953/4885 |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | PDK1 3187/4885PDK2 2987/4885PDK3 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.